Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kjell Fuxe, Diego Guidolin, Luigi F Agnati & Dasiel O Borroto-Escuela. (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opinion on Therapeutic Targets 19:3, pages 377-398.
Read now
Read now
Nataša Klepac, Mario Habek, Ivan Adamec, Anabella Karla Barušić, Ivo Bach, Eduard Margetić & Ivo Lušić. (2012) An update on the management of young-onset Parkinson’s disease. Degenerative Neurological and Neuromuscular Disease 2, pages 53-62.
Read now
Read now
Articles from other publishers (9)
Riya Mahar, Arpita Chakraborty & Nidhi Nainwal. (2022) The influence of carrier type, physical characteristics, and blending techniques on the performance of dry powder inhalers. Journal of Drug Delivery Science and Technology 76, pages 103759.
Crossref
Crossref
Pallavi Rane, Deepaneeta Sarmah, Shashikala Bhute, Harpreet Kaur, Avirag Goswami, Kiran Kalia, Anupom Borah, Kunjan R. Dave, Nutan Sharma & Pallab Bhattacharya. (2018) Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums. ACS Chemical Neuroscience 10:1, pages 44-57.
Crossref
Crossref
Xu Jiang, Palanivel Ganesan, Thamaraiselvan Rengarajan, Dong-Kug Choi & Palanisamy Arulselvan. (2018) Cellular phenotypes as inflammatory mediators in Parkinson’s disease: Interventional targets and role of natural products. Biomedicine & Pharmacotherapy 106, pages 1052-1062.
Crossref
Crossref
Nazrul Islam & Matthew J. Cleary. (2012) Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery – A review for multidisciplinary researchers. Medical Engineering & Physics 34:4, pages 409-427.
Crossref
Crossref
. 2011. A Guide to Evidence-based Integrative and Complementary Medicine. A Guide to Evidence-based Integrative and Complementary Medicine
715
730
.
Mark J. Millan. (2010) From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacology & Therapeutics 128:2, pages 229-273.
Crossref
Crossref
Teri R. Thomsen & Robert L. Rodnitzky. (2010) Juvenile Parkinsonism. CNS Drugs 24:6, pages 467-477.
Crossref
Crossref
Katia Varani, Fabrizio Vincenzi, Alice Tosi, Stefania Gessi, Ilaria Casetta, Gino Granieri, Patrik Fazio, Edward Leung, Stephen MacLennan, Enrico Granieri & Pier Andrea Borea. (2009)
A
2A
adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease
. The FASEB Journal 24:2, pages 587-598.
Crossref
Crossref
R Reiter, S Paredes, A Korkmaz, L Manchester & D Tan. (2008) Melatonin in relation to the "strong" and "weak" versions of the free radical theory of aging. Advances in Medical Sciences 53:2.
Crossref
Crossref